CN118284412A - 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗 - Google Patents

伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗 Download PDF

Info

Publication number
CN118284412A
CN118284412A CN202280077354.9A CN202280077354A CN118284412A CN 118284412 A CN118284412 A CN 118284412A CN 202280077354 A CN202280077354 A CN 202280077354A CN 118284412 A CN118284412 A CN 118284412A
Authority
CN
China
Prior art keywords
cbd
asd
irritability
subject
abc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280077354.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·帕伦博
S·V·奥奎因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zyne Pharmaceutical Co
Original Assignee
Zyne Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zyne Pharmaceutical Co filed Critical Zyne Pharmaceutical Co
Publication of CN118284412A publication Critical patent/CN118284412A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280077354.9A 2021-10-22 2022-10-20 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗 Pending CN118284412A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163271015P 2021-10-22 2021-10-22
US63/271,015 2021-10-22
PCT/US2022/078449 WO2023070045A1 (en) 2021-10-22 2022-10-20 Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance

Publications (1)

Publication Number Publication Date
CN118284412A true CN118284412A (zh) 2024-07-02

Family

ID=84358575

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280077354.9A Pending CN118284412A (zh) 2021-10-22 2022-10-20 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗

Country Status (10)

Country Link
US (1) US20240342198A1 (enExample)
EP (1) EP4419091A1 (enExample)
JP (1) JP2024536581A (enExample)
KR (1) KR20240093852A (enExample)
CN (1) CN118284412A (enExample)
AU (1) AU2022373753A1 (enExample)
CA (1) CA3235677A1 (enExample)
IL (1) IL312328A (enExample)
MX (1) MX2024004766A (enExample)
WO (1) WO2023070045A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2760460C (en) 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
CA3300266A1 (en) * 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
WO2019224824A1 (en) * 2018-05-24 2019-11-28 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
US20210369643A1 (en) * 2020-05-26 2021-12-02 Zynerba Pharmaceuticals, Inc. Treatment of fragile x syndrome and autism spectrum disorder with cannabidiol
BR112022026044A2 (pt) * 2020-06-29 2023-03-07 Zynerba Pharmaceuticals Inc Tratamento de síndrome do x frágil com canabidiol
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs

Also Published As

Publication number Publication date
JP2024536581A (ja) 2024-10-04
AU2022373753A1 (en) 2024-05-09
EP4419091A1 (en) 2024-08-28
IL312328A (en) 2024-06-01
WO2023070045A1 (en) 2023-04-27
KR20240093852A (ko) 2024-06-24
US20240342198A1 (en) 2024-10-17
CA3235677A1 (en) 2023-04-27
MX2024004766A (es) 2024-06-11

Similar Documents

Publication Publication Date Title
US12213951B2 (en) Treatment of autism with cannabidiol
US12186282B2 (en) Treatment of 22Q11.2 deletion syndrome with cannabidiol
KR20200113197A (ko) 우울증 치료를 위한 에스케타민
US20210030665A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
US20210196669A1 (en) Cannabis-based compositions for the treatment of autistic spectrum disorders
US12582664B2 (en) Treatment of fragile x syndrome with cannabidiol
US20240342198A1 (en) Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance
JP7830358B2 (ja) カンナビジオールによる脆弱ｘ症候群の処置
US20250288539A1 (en) Treatment of fragile x syndrome and autism spectrum disorder with cannabidiol
US20230000793A1 (en) Treatment of 22q11.2 deletion syndrome with cannabidiol
US20230000792A1 (en) Treatment of 22q11.2 deletion syndrome with cannabidiol
US20250177322A1 (en) Treatment of fragile x syndrome with cannabidiol
BR122024006812A2 (pt) Creme, pomada ou emplastro, curativo, compressa ou adesivo e uso de uma quantidade eficaz de canabidiol (cbd)

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Pennsylvania, USA

Applicant after: Harmony Biological Science Management Co.,Ltd.

Address before: Pennsylvania, USA

Applicant before: Zyne pharmaceutical Co.

Country or region before: U.S.A.